ClinicalTrials.gg
RecruitingNCT05131035SCORESUpdated Nov 24, 2025

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk

An interventional study of SCORES (Specific COgnitive Remediation with Support) in Psychosis, Prodromal Schizophrenia and Prodromal Symptoms, sponsored by Northwell Health. Recruiting at 1 site in United States. Open to participants aged 14 Years to 20 Years. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Northwell Health · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
14 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Psychotic Disorders by Northwell Health — 4 open to participants now, 4 under way, none of them phase 3. Psychotic Disorders · Northwell Health.

Planned enrollment
10th of 16
54 · median 72
Started
2021
the only one that year
No phase
12 of 18
3 open now
Registered
15th of 18
by date

Among the 18 studies in Psychotic Disorders by Northwell Health, this one is the 10th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2021, is one of 12 with no phase, and was the 15th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

4 of the 18 studies in Psychotic Disorders by Northwell Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 14 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Psychotic Disorders by Northwell Health, or all of them as a file.
02

Study summary

This 10 week intervention, Specific Cognitive Remediation with Surround (or SCORES), is designed to target processing speed, a cognitive domain related directly to social functioning, which in turn, represents a vulnerability factor for psychosis. This remotely-delivered intervention combining targeted cognitive training exercises and group support was developed to directly impact processing speed, and at the same time, boost motivation and engagement in adolescents at risk for schizophrenia and other psychotic disorders.

Read the detailed description

This study evaluates the effectiveness of a cognitive remediation (CR) program plus group coaching and support designed to improve processing speed and, in turn, social functioning and attenuated positive symptoms in individual considered Clinical High Risk for psychosis. The SCORES (Specific COgnitive REmediation with Support) intervention is a novel Cognitive Remediation program combined with group coaching, performance-based rewards, game-like tasks, and educational elements to increase engagement and retention. The study is funded by a R61/R33 award. In the R61 phase, all participants were asked to complete 40 hours of Cognitive Remediation or brain training (4 hours per week/10 weeks) with a mid-point assessment (at 5 weeks) to determine the training dose needed to impact processing speed as measured by the Matrics Cognitive Consensus Battery. The current R33 (Phase 2) will look to replicate the results of the R61 and assess the specificity of the targeted intervention with the addition of a non-speeded cognitive training group..

03

Conditions studied

  • Psychosis
  • Prodromal Schizophrenia
  • Prodromal Symptoms

Keywords

  • Clinical High Risk (CHR)
  • Processing Speed
  • Social Functioning
  • Social Impairment
  • Social Skills
  • Adolescents
  • Cognitive Remediation
04

Who can participate

Ages eligible
14 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet Clinical High Risk (CHR) criteria on the Structured Interview for Psychosis Risk Syndromes, defined by the presence of at least one attenuated positive symptom at a moderate to severe level
  • A score representing 0.5 SD below the mean on Animal Naming, Trails A or BACS: Symbol Coding from the MATRICS Consensus Cognitive Battery (MCCB).

Exclusion criteria

Exclusion Criteria:

  • Any DSM 5 Schizophrenia-Spectrum diagnosis
  • Non-English speaking
  • Past or current history of a central nervous system disorder (e.g., seizure disorder)
  • Estimated IQ\<70
  • Significant head injury
  • Significant substance abuse
  • Significant visual or auditory impairment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Speeded Cognitive Training

    Participants in this condition will complete 40 hours of Cognitive Remediation with a mid-point assessment (20 hours/5 weeks) to determine the impact of speeded cognitive training tasks on cognition and social function.

    Behavioral: SCORES (Specific COgnitive Remediation with Support)

  • Active comparator
    Non-Speeded Cognitive Training

    Participants in this condition will complete 40 hours of Cognitive Remediation with a mid-point assessment (20 hours/5 weeks) to determine the impact of non-speeded cognitive training tasks on cognition and social function.

    Behavioral: SCORES (Specific COgnitive Remediation with Support)

Interventions

  • BehavioralSCORES (Specific COgnitive Remediation with Support)

    This study evaluates the effectiveness of a 10-week cognitive remediation program plus group coaching and therapy to improve processing speed and, in turn, social functioning and attenuated positive symptoms in CHR subjects. The SCORES (Specific COgnitive Remediation with Support) intervention is a novel CR program combined with group coaching, performance-based rewards, game-like tasks, and therapy elements to increase engagement and retention. In the 2 year, R61 phase, all participants will complete 40 hours of CR (4 hrs per week) with a mid-point assessment (20 hours of CR at 5 weeks) to determine the impact of CR on processing speed as measured by the MCCB. The second phase of the study (R33) will compare the 40 hours of speeded brain training to 40 hours of non-speeded brain training. This three year study will allow for a replication and assessment of specificity of the targeted intervention.

06

What researchers measure

Primary outcomes

  1. Processing Speed domain score from the MATRICS Consensus Cognitive Battery (MCCB)

    Change in processing speed domain score and individual measures within the domain.

    Time frame: Baseline, Mid-Treatment (5 weeks), Post Treatment (10 weeks)

Secondary outcomes

  1. Global Functioning: Social (GF:Social) scale (Phase 2/R33 only)

    Change in GF:Social score from baseline to follow up timepoints. The GF:Social scale scores range from 1 to 10 with higher scores representing better social functioning.

    Time frame: Baseline, Mid-Treatment (5 weeks), Post Treatment (10 weeks)

  2. SIPS/SOPS: Positive Symptoms (Phase 2/R33 only)

    Change in Total Positive Symptom score from baseline to follow up timepoints. Each of the 5 positive symptoms on the SOPS range from 0-6 (6 indicating a psychotic symptom).

    Time frame: Baseline, Mid-Treatment (5 weeks), Post Treatment (10 weeks)

07

Study locations

1 of 1 sites recruiting
  • Northwell Health- The Zucker Hillside Hospital
    Glen Oaks, New York 11042, United States
    Recruiting
    • Andrea M Auther, Ph.D. · Contactaauther@northwell.edu · 718-470-8147
    • Danielle McLaughlin, M.A. · Contactdmclaugh@northwell.edu · 718-470-8375
    • Barbara A Cornblatt, Ph.D. · Principal investigator
    • Ricardo E Carrion, Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Data will be uploaded to the NIH Data Archive (NDA).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: We plan to make all data collected available as a national resource to the broader scientific community for investigators wishing to pursue their own analyses. Consistent with the NIH policy regarding data sharing, we will share data no later than following acceptance for publication of the main findings from the final dataset, which is expected to occur at the end of year 5. We request that we maintain exclusive access to these data until the end of year 5 to ensure an adequate amount of time for the PIs to conduct analyses and prepare manuscripts for publication. All de-identified data resulting from this NIH-funded award will be submitted to the NIMH Data Archive (NDA) according to this timeline, along with appropriate supporting documentation to enable efficient use of the data by other researchers not involved in the study. Data derived from the proposed study will also be shared through presentation at research conferences and through publication in peer-reviewed journals.

Access criteria: Data will be shared with researchers upon request. Other researchers across the world can then request the pseudo-anonymized study data for other research from the NDA. Every researcher (and institutions to which they belong) who requests the pseudo-anonymized study data must promise to keep the data safe. Experts at the NIH will review each request carefully to reduce risks to participant privacy.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for May 2026, 55 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 55 months is above that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2021
First posted
Nov 23, 2021
StartActual
Oct 28, 2021
Primary completionEst.
May 31, 2026
CompletionEst.
May 31, 2026
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05131035
Lead sponsor
Northwell Health
Responsible party
Sponsor
First posted
Nov 23, 2021
Start date
Oct 28, 2021
Primary completion
May 31, 2026 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Nov 24, 2025

Study contacts

Ricardo E Carrion, Ph.D.
Contact
rcarrion@northwell.edu
718-470-8788
Danielle McLaughlin, M.A.
Contact
dmclaugh@northwell.edu
718-470-8375
Ricardo E Carrion, Ph.D.
principal investigator · Northwell Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion